This exacerbation followed a recent change in her diabetes regimen; She had been transitioned from a combination of long-acting insulin (40 units nightly) and short-acting insulin (10 units before meals) to tirzepatide (Mounjaro), a dual GLP-1/GIP receptor agonist, approximately seven weeks prior to presentation. The gene discussed is GLP1R; the disease is diabetes mellitus.